Clinical Effects of Shengbai Kangfu Oral Liquid Combined with PEG-rhG-CSF in Treatment of Chemotherapy-related Granulocytopenia in Breast Cancer
Objective To analyze clinical effects of Shengbai Kangfu Oral Liquid combined with PEG-rhG-CSF in treatment of chemotherapy-related granulocytopenia in breast cancer.Methods One hundred cases of breast cancer patients with Ⅲ～Ⅳ degree myelosuppression after the first chemotherapy were selected as research subjects.The patients were grouped using a random envelope method.Those treated with PEG-rhG-CSF after the end of re-chemotherapy constituted control group(50 cases),while those treated with a combined use of Shengbai Kangfu Oral Liquid in addition to PEG-rhG-CSF formed experimental group(50 cases).Both groups were treated for 14 days.The changes in the levels of white blood cells(WBC)and absolute neutrophil count(ANC),as well as ANC grading and adverse reactions,were compared between the two groups before and after chemotherapy.Results After chemo-therapy,the levels of WBC and ANC in both groups of patients decreased significantly compared to before chemotherapy,and the levels of both indicators in experimental group were higher than those in control group(P<0.01).After chemotherapy,the proportion of ANC grades Ⅰ and Ⅱ in experimental group was higher than that in control group(P<0.01),while the proportion of ANC grades Ⅲ and Ⅳ was lower than that in control group(P<0.01).The incidence of adverse reactions in experimental group was lower than that of control group(P<0.05).Conclusion The combination of Shengbai Kangfu Oral Lquid and PEG-rhG-CSF can reduce chemotherapy-related granulocytopenia and adverse reactions in breast cancer.
国家科技期刊平台
NSTL
万方数据
